Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease

Neurobiology of Disease

Volumn 73, Issue , 2015, Pages 70-82

  Nordström, Ulrika ^a   Beauvais, Geneviève ^b   Ghosh, Anamitra ^b   Pulikkaparambil Sasidharan, Baby Chakrapani ^b   Lundblad, Martin ^a   Fuchs, Julia ^c,g,h   Joshi, Rajiv L ^c,g,h   Lipton, Jack W ^b,d   Roholt, Andrew ^e   Medicetty, Satish ^e   Feinstein, Timothy N ^f   Steiner, Jennifer A ^b   Escobar Galvis, Martha L ^b   Prochiantz, Alain ^c,g,h   Brundin, Patrik ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b VAN ANDEL RESEARCH INSTITUTE   (United States)

^c PSL RESEARCH UNIVERSITY   (France)

^d CNRS   (France)

^e INSERM   (France)

^f MICHIGAN STATE UNIVERSITY   (United States)

^g MICHIGAN STATE UNIVERSITY   (United States)

^h Renovoneural Inc   (United States)

Author keywords

Autophagy; CLARITY; Dopamine transporter; En1+ mice; Impaired dopamine release; In vivo electrochemistry; LC3; MTOR; Retrograde degeneration; TH GFP

Indexed keywords

DOPAMINE TRANSPORTER; ENGRAILED 1 PROTEIN; HOMEODOMAIN PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MICROTUBULE ASSOCIATED PROTEIN LIGHT CHAIN 3B; MICROTUBULE PROTEIN; TRANSCRIPTION FACTOR; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2; 3,4 DIHYDROXYPHENYLACETIC ACID; EN1 PROTEIN, MOUSE; GREEN FLUORESCENT PROTEIN; HOMOVANILLIC ACID; MTOR PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE;

ADULT; ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CELL VACUOLE; CONTROLLED STUDY; CORPUS STRIATUM; DENSE BODY; DOPAMINE RELEASE; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; DOWN REGULATION; ELECTROCHEMISTRY; EN1 GENE; GENE; HETEROZYGOTE; IN VIVO STUDY; MESENCEPHALON; MOUSE; NERVE DEGENERATION; NERVE ENDING; NERVE FIBER; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; STRIA TERMINALIS; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; ANIMAL; COMPLICATION; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SUBSTANTIA NIGRA; TIME; TRANSGENIC MOUSE; ULTRASTRUCTURE;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; AUTOPHAGY; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOPAMINERGIC NEURONS; GENE EXPRESSION REGULATION; GREEN FLUORESCENT PROTEINS; HOMEODOMAIN PROTEINS; HOMOVANILLIC ACID; MICE; MICE, TRANSGENIC; NERVE DEGENERATION; PARKINSON DISEASE; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; TIME FACTORS; TOR SERINE-THREONINE KINASES; TYROSINE 3-MONOOXYGENASE;

EID: 84908409010     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.09.012     Document Type: Article

References (47)

1. Alvarez-Fischer D., et al. Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults. Nat. Neurosci. 2011, 14:1260-1266.
2. Bezard E., et al. Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. Mov. Disord. 2013, 28:61-70.
3. Blesa J., et al. Classic and new animal models of Parkinson's disease. J. Biomed. Biotechnol. 2012, 2012:845618.
4. Brunet I., et al. The transcription factor Engrailed-2 guides retinal axons. Nature 2005, 438:94-98.
5. Burke R.E., O'Malley K. Axon degeneration in Parkinson's disease. Exp. Neurol. 2013, 246:72-83.
6. Cheng H.C., et al. Clinical progression in Parkinson's disease and the neurobiology of axons. Ann. Neurol. 2010, 67:715-725.
7. Chu Y., et al. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain 2012, 135:2058-2073.
8. Chung K., et al. Structural and molecular interrogation of intact biological systems. Nature 2013, 497:332-337.
9. Coleman M.P., Perry V.H. Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci. 2002, 25:532-537.
10. Decressac M., et al. alpha-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci. Transl. Med. 2012, 4:163ra156.
11. Dehay B., et al. Pathogenic lysosomal depletion in Parkinson's disease. J. Neurosci. 2010, 30:12535-12544.
12. Deleidi M., Maetzler W. Protein clearance mechanisms of alpha-synuclein and amyloid-Beta in Lewy body disorders. Int. J. Alzheimers Dis. 2012, 391438.
13. Exner N., et al. Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J. 2012, 31:3038-3062.
14. Fuchs J., et al. The transcription factor PITX3 is associated with sporadic Parkinson's disease. Neurobiol. Aging 2009, 30:731-738.
15. Galvin J.E., et al. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:13450-13455.
16. Hansen C., et al. A novel alpha-synuclein-GFP mouse model displays progressive motor impairment, olfactory dysfunction and accumulation of alpha-synuclein-GFP. Neurobiol. Dis. 2013, 56:145-155.
17. Jackson-Lewis V., et al. Developmental cell death in dopaminergic neurons of the substantia nigra of mice. J. Comp. Neurol. 2000, 424:476-488.
18. Kadkhodaei B., et al. Transcription factor Nurr1 maintains fiber integrity and nuclear-encoded mitochondrial gene expression in dopamine neurons. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:2360-2365.
19. Kagi G., et al. The role of DAT-SPECT in movement disorders. J. Neurol. Neurosurg. Psychiatry 2010, 81:5-12.
20. Kordower J.H., et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013, 136:2419-2431.
21. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
22. Le Pen G., et al. Progressive loss of dopaminergic neurons in the ventral midbrain of adult mice heterozygote for Engrailed1: a new genetic model for Parkinson's disease?. Parkinsonism Relat. Disord. 2008, 14(Suppl. 2):S107-S111.
23. Le W.D., et al. Mutations in NR4A2 associated with familial Parkinson disease. Nat. Genet. 2003, 33:85-89.
24. Lundblad M., et al. Impaired neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:3213-3219.
25. Malagelada C., et al. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J. Neurosci. 2010, 30:1166-1175.
26. Mizuno Y., et al. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 1989, 163:1450-1455.
27. Pan T., et al. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain 2008, 131:1969-1978.
28. Pickel V.M., et al. Ultrastructural immunocytochemical localization of tyrosine hydroxylase in the neostriatum. Brain Res. 1981, 225:373-385.
29. Pissadaki E.K., Bolam J.P. The energy cost of action potential propagation in dopamine neurons: clues to susceptibility in Parkinson's disease. Front. Comput. Neurosci. 2013, 7:13.
30. Poulin J.-F., Drouin-Ouellet J., Cicchetti F., Awatramani R.B. High throughput single-cell expression analysis of midbrain dopamine neurons reveals Aldh1a1 as marker of vulnerability in a model of Parkinson's disease. Program No. 46.08. 2013 Neuroscience Meeting Planner. 2013, Society for Neuroscience, San Diego, CA, 2013. Online.
31. Poulin J.-F., et al. Defining midbrain dopaminergic neuron diversity by single-cell gene profiling. Cell Rep. 2014, (in press).
32. Sanchez-Perez A.M., et al. Parkinson's disease and autophagy. Park. Dis. 2012, 429524.
33. Sawamoto K., et al. Visualization, direct isolation, and transplantation of midbrain dopaminergic neurons. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:6423-6428.
34. Schapira A.H. Mitochondrial pathology in Parkinson's disease. Mt Sinai J. Med. 2011, 78:872-881.
35. Schapira A.H., et al. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989, 1:1269.
36. Schapira A.H., et al. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 1990, 54:823-827.
37. Simon H.H., et al. Fate of midbrain dopaminergic neurons controlled by the engrailed genes. J. Neurosci. 2001, 21:3126-3134.
38. Son J.H., et al. Neuronal autophagy and neurodegenerative diseases. Exp. Mol. Med. 2012, 44:89-98.
39. Sonnier L., et al. Progressive loss of dopaminergic neurons in the ventral midbrain of adult mice heterozygote for Engrailed1. J. Neurosci. 2007, 27:1063-1071.
40. Spieles-Engemann A.L., et al. Stimulation of the rat subthalamic nucleus is neuroprotective following significant nigral dopamine neuron loss. Neurobiol. Dis. 2010, 39:105-115.
41. Stettler O., et al. Engrailed homeoprotein recruits the adenosine A1 receptor to potentiate ephrin A5 function in retinal growth cones. Development 2012, 139:215-224.
42. Veenvliet J.V., et al. Specification of dopaminergic subsets involves interplay of En1 and Pitx3. Development 2013, 140:3373-3384.
43. Wizenmann A., et al. Extracellular Engrailed participates in the topographic guidance of retinal axons in vivo. Neuron 2009, 64:355-366.
44. Wurst W., et al. Multiple developmental defects in Engrailed-1 mutant mice: an early mid-hindbrain deletion and patterning defects in forelimbs and sternum. Development 1994, 120:2065-2075.
45. Yamamoto A., Yue Z. Autophagy and its normal and pathogenic States in the brain. Annu. Rev. Neurosci. 2014, 37:55-78.
46. Yang Y., et al. Autophagy in axonal and dendritic degeneration. Trends Neurosci. 2013, 36:418-428.
47. Yoon B.C., et al. Local translation of extranuclear lamin B promotes axon maintenance. Cell 2012, 148:752-764.